Skip to main content
. 2015 Mar 12;6(8):5501–5516. doi: 10.18632/oncotarget.3551

Figure 4. BRD3 and BRDT inhibitors and their relevant anti-cancer pathways.

Figure 4

(A) Fused with NUT gene, BRD3 may encode BRD3-NUT fusion proteins in NMC, which is similar with BRD4. Specifically inhibiting BRD3-NUT fusion protein can block BRD3-NUT gene transcription, and inhibit NMC cell growth. (B) Pan-inhibitors I-BET762 and JQ1 inhibits BRD3. (C) As the only member of BET family can bind with transcription factor GATA1, inhibition of BRD3 through BRD3-GATA pathway by clinical experimental compound, RVX-208, may be a therapeutic strategy in hepatocellular carcinoma. (D) The least known BET family member, BRDT, is also been detected the anti-cancer capacity in leukemia by an unspecific-target drug Dinaciclib.